4//SEC Filing
OrbiMed Israel GP Ltd. 4
Accession 0000947871-21-000844
CIK 0001739174other
Filed
Jul 29, 8:00 PM ET
Accepted
Jul 30, 6:20 PM ET
Size
11.1 KB
Accession
0000947871-21-000844
Insider Transaction Report
Form 4
BiomX Inc.PHGE
OrbiMed Israel GP Ltd.
10% Owner
Transactions
- Purchase
Warrants (Right to Buy)
2021-07-28+375,000→ 375,000 total(indirect: See Footnotes)Exercise: $5.00From: 2022-01-28Exp: 2027-01-28→ Common Stock (375,000 underlying) - Purchase
Common Stock, $0.0001 par value
2021-07-28+500,000→ 2,813,489 total(indirect: See Footnotes)
Transactions
- Purchase
Common Stock, $0.0001 par value
2021-07-28+500,000→ 2,813,489 total(indirect: See Footnotes) - Purchase
Warrants (Right to Buy)
2021-07-28+375,000→ 375,000 total(indirect: See Footnotes)Exercise: $5.00From: 2022-01-28Exp: 2027-01-28→ Common Stock (375,000 underlying)
Footnotes (3)
- [F1]In the Issuer's underwritten public offering, OrbiMed Israel Partners Limited Partnership ("OIP") purchased units that included 500,000 shares of the Issuer's common stock and 375,000 warrants, each exercisable for 1 share of the Issuer's common stock. The purchase price of each unit was $4.00.
- [F2]The purchase reported on this Form 4 were made by OIP. Following the transactions reported on this Form 4, OIP LP is the direct owner of 2,172,150 of these shares of common stock and OrbiMed Israel Incubator Limited Partnership ("OII") is the direct owner of 641,339 of these shares of common stock. OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund"), which is the general partner of OIP and OII. By virtue of these relationships, OrbiMed Israel and OrbiMed BioFund may be deemed to have voting and investment power over the securities held by OIP and OII and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Israel exercises investment and voting power through an investment committee comprised of Carl L. Gordon, Nissim Darvish, Anat Naschitz, and Erez Chimovits.
- [F3]This report on Form 4 is jointly filed by OrbiMed Israel and OrbiMed BioFund. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
BiomX Inc.
CIK 0001739174
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 4
- Filed
- Jul 29, 8:00 PM ET
- Accepted
- Jul 30, 6:20 PM ET
- Size
- 11.1 KB